Corcept Therapeutics

American pharmaceutical company

CORT Nasdaq ISIN US2183521028 SEC CIK 1088856
Follow Corcept Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $340.5M +64% vs same quarter last year
Net income $126.8M +544.6% vs same quarter last year
EPS, diluted $1.01 +531.3% vs same quarter last year
Operating cash flow $142.9M +162.3% vs same quarter last year
Revenue by quarter
$181.9M
$157.2M
$194.4M
$207.6M
$202.1M
$164.9M
$256.1M
$340.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$250M$0$250M$500M$750M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$761.4M$99.7M
FY24$675M$141.2M
FY23$482.4M$106.1M
FY22$401.9M$101.4M
FY21$366M$112.5M
FY20$353.9M$106M
FY19$306.5M$94.2M
FY18$251.2M$75.4M
FY17$159.2M$129.1M
FY16$81.3M$8.1M
FY15$50.3M−$6.4M
FY14$26.6M−$31.4M
FY13$10.4M−$46M
FY12$3.3M−$38M
FY11-−$32.4M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2598.3%5.9%13.1%
FY2498.4%20.3%20.9%
FY2398.7%22.2%22%
FY2298.7%28%25.2%
FY2198.6%34%30.7%
FY2098.4%36.2%30%
FY1998.2%36.4%30.7%
FY1897.9%35.6%30%
FY1797.8%33.2%81.1%
FY1697.5%12.5%10%
FY1597.3%−6.8%−12.7%
FY1496.7%−104%−118.2%
FY1398.6%−400.7%−444.3%
FY1297.2%−1096.8%−1150.5%
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$141.8M
FY24$196.1M
FY23$126.5M
FY22$119.9M
FY21$167.4M
FY20$150.7M
FY19$135M
FY18$115.4M
FY17$60.5M
FY16$18.2M
FY15$3.1M
FY14−$27.6M
FY13−$37.2M
FY12−$36.2M
FY11−$27.4M
Returned to shareholdersDividends paid and shares bought back
$0$50M$100M$150M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$172.9M
FY24$15.7M
FY23$0
FY22$0
FY21-
FY20$9.9M
FY19$31M
FY18$23.7M
FY17$0
FY16$0
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Corcept Therapeutics
  • Healthcare median
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCorcept TherapeuticsHealthcare median
FY2513.1%−30.6%
FY2420.9%−47%
FY2322%−58%
FY2225.2%−80.4%
FY2130.7%−71.8%
FY2030%−62.2%
FY1930.7%−46.2%
FY1830%−49.6%
FY1781.1%−45.9%
FY1610%−36%
FY15−12.7%−37.8%
FY14−118.2%−35.5%
FY13−444.3%−37.1%
FY12−1150.5%−29.1%
FY11-−27.9%